Evidence map›Paper›PMID 30832318›Full record

ArticleCells2019

ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells.

Metin Cetin, Gorkem Odabas, Leon R Douglas, Patrick J Duriez, Pelin Balcik-Ercin, Irem Yalim-Camci, Abdulkadir Emre Sayan, Tamer Yagci

Open access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. ADRM1 as a therapeutic target in hepatocellular carcinoma.The Kaohsiung journal of medical sciences · 2021
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Metin CetinDepartment of Molecular Biology and Genetics, Gebze Technical University, Kocaeli 41400, Turkey. metincetin@gtu.edu.tr.
Gorkem OdabasDepartment of Molecular Biology and Genetics, Gebze Technical University, Kocaeli 41400, Turkey. godabas@gtu.edu.tr.
Leon R DouglasProtein Core Facility, Cancer Research UK and Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK. L.R.Douglas@soton.ac.uk.
Patrick J DuriezProtein Core Facility, Cancer Research UK and Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK. P.J.Duriez@soton.ac.uk.
Pelin Balcik-ErcinDepartment of Molecular Biology and Genetics, Gebze Technical University, Kocaeli 41400, Turkey. pbalcik@gtu.edu.tr.
Irem Yalim-CamciDepartment of Molecular Biology and Genetics, Gebze Technical University, Kocaeli 41400, Turkey. iyalim@gtu.edu.tr.
Abdulkadir Emre SayanCancer Sciences Unit and Cancer Research UK Centre, University of Southampton, Southampton General Hospital, Somers Cancer Research Building, Mailpoint 824, Southampton SO16 6YD, UK. a.e.sayan@soton.ac.uk.
Tamer YagciDepartment of Molecular Biology and Genetics, Gebze Technical University, Kocaeli 41400, Turkey. tyagci@gtu.edu.tr.ORCID 0000-0003-2050-7477
Gebze Technical University · TRCancer Research UK · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a common and deadly cancer; however, very little improvement has been made towards its diagnosis and prognosis. The expression and functional contribution of the receptor tyrosine kinase ROR1 have not been investigated in HCC before. Hence, we investigated the expression of ROR1 in HCC cells and assessed its involvement in hepatocarcinogenesis.

methodsRecombinant bacterial ROR1 protein was used as an immunogen to generate ROR1 monoclonal antibodies.

resultsNew ROR1 antibodies specifically detected endogenous ROR1 protein in human and mouse HCC cell lines. ROR1-knockdown resulted in decreased proliferation and migration but enhanced resistance to apoptosis and anoikis. The observed chemotherapy-resistant phenotype of ROR1-knockdown cells was due to enhanced drug efflux and increased expression of multi-drug resistance genes.

conclusionsROR1 is expressed in HCC and contributes to disease development by interfering with multiple pathways. Acquired ROR1 expression may have diagnostic and prognostic value in HCC.

Indexed as

AnimalsAnoikisAntibodies, MonoclonalAntineoplastic AgentsApoptosisCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionG1 PhaseGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMiceAntibodies, MonoclonalAntineoplastic AgentsReceptor Tyrosine Kinase-like Orphan Receptorsdrug effluxdrug resistanceEMThallmarks of cancerHCCmonoclonal antibodyROR1

Identifiers

PMID30832318
PMCPMC6468649
OpenAlexW2920509563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.